MedTrace Logo

TroVax Renal Immunotherapy Survival Trial

NCT00397345 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 733

Last updated 2020-10-19

No results posted yet for this study

Summary

The purpose of this study is to investigate whether TroVax, when added to first line standard of care therapy, improves survival for patients with locally advanced or metastatic clear cell renal adenocarcinoma.

Conditions

  • Clear Cell Renal Carcinoma

Interventions

BIOLOGICAL

Trovax

1ml IM injection 2-8 weeks apart.

BIOLOGICAL

Placebo

Placebo

BIOLOGICAL

Standard of care therapy

subcutaneous low dose IL-2, interferon-α or sunitinib

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Oxford BioMedica

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States
  • France
  • Germany
  • Israel
  • Poland
  • Romania
  • Russia
  • Spain
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00397345 on ClinicalTrials.gov